|
WO2009126688A2
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
*
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
US12202856B2
(en)
|
2016-05-19 |
2025-01-21 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
EP3841123A2
(en)
*
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anti-tigit antibodies
|
|
US11376255B2
(en)
|
2018-09-11 |
2022-07-05 |
iTeos Belgium SA |
Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
|
|
KR20250035608A
(ko)
|
2018-09-11 |
2025-03-12 |
아이테오스 벨지움 에스에이 |
A2a 억제제로서 싸이오카바메이트 유도체, 이의 약학 조성물 및 항암제와의 조합물
|
|
WO2020127377A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional anti-pd-1/il-7 molecule
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
US20200318200A1
(en)
|
2019-04-02 |
2020-10-08 |
The Brigham And Women's Hospital, Inc. |
Methods for Identifying Progression of a Primary Melanoma
|
|
CA3139641A1
(en)
*
|
2019-06-13 |
2020-12-17 |
Green Cross Corporation |
Antibody to tigit and use thereof
|
|
CA3143995A1
(en)
*
|
2019-06-21 |
2020-12-24 |
Single Cell Technology, Inc. |
Anti-tigit antibodies
|
|
CN114728171A
(zh)
*
|
2019-11-05 |
2022-07-08 |
默克专利有限公司 |
抗tigit抗体及其应用
|
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ｏｓｅ免疫治療公司 |
包含il-7變體之雙官能分子
|
|
CN112409450B
(zh)
*
|
2020-03-29 |
2023-01-24 |
郑州大学 |
TIGIT-IgV的亲和剂及其应用
|
|
CN113563470B
(zh)
*
|
2020-04-29 |
2023-02-10 |
广州昂科免疫生物技术有限公司 |
结合tigit抗原的抗体及其制备方法与应用
|
|
EP4147053B1
(en)
|
2020-05-07 |
2026-01-28 |
Institut Curie |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN111995681B
(zh)
*
|
2020-05-09 |
2022-03-08 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
TW202210514A
(zh)
|
2020-06-02 |
2022-03-16 |
美商阿克思生物科學有限公司 |
針對tigit的抗體
|
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
WO2021258337A1
(en)
*
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
CN111718415B
(zh)
*
|
2020-07-03 |
2021-02-23 |
上海洛启生物医药技术有限公司 |
一种抗tigit纳米抗体及其应用
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
CA3189730A1
(en)
*
|
2020-08-05 |
2022-02-10 |
Crystal Bioscience Inc. |
Anti-tigit antibody and methods of use thereof
|
|
EP4225792A1
(en)
|
2020-10-08 |
2023-08-16 |
Affimed GmbH |
Trispecific binders
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
WO2022178135A1
(en)
|
2021-02-17 |
2022-08-25 |
Iteos Belguim Sa |
Compounds, compositions and methods of treatment thereof
|
|
MX2023011964A
(es)
|
2021-04-09 |
2024-01-08 |
Ose Immunotherapeutics |
Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
CA3217279A1
(en)
|
2021-05-04 |
2022-11-10 |
Olga Ignatovich |
Anti-tigit antibodies and methods of use thereof
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
CN118871463A
(zh)
|
2021-07-28 |
2024-10-29 |
基因泰克公司 |
用于治疗癌症的方法和组合物
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
KR20240043786A
(ko)
*
|
2021-08-09 |
2024-04-03 |
바이오세우스 인크. |
항-tigit 항체 및 이의 용도
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
CN119156228A
(zh)
|
2022-05-02 |
2024-12-17 |
艾库斯生物科学有限公司 |
抗tigit抗体及其用途
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
EP4565610A1
(en)
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
WO2024200820A1
(en)
|
2023-03-30 |
2024-10-03 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025255297A1
(en)
*
|
2024-06-05 |
2025-12-11 |
Agilent Technologies, Inc. |
Anti-human tigit antibodies for in vitro diagnostics
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|